<DOC>
	<DOCNO>NCT01287858</DOCNO>
	<brief_summary>AC430 administer , orally fast condition ( fast 4 hour 2 hour dose ) approximately 240 mL water either daily twice daily . It design assess safety , tolerability , pharmacokinetics single multiple oral dos AC430 .</brief_summary>
	<brief_title>Study Assess Safety , Tolerability , Pharmacokinetics Oral Doses AC430 Healthy Subjects</brief_title>
	<detailed_description>A dose-finding study AC430 healthy volunteer .</detailed_description>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<criteria>Important 1 . Healthy normal male female , age 18 45 , inclusive , time consent 2 . Able communicate effectively English language 3 . Able provide valid , write informed consent 4 . Able swallow 20 capsule study drug 5 . BMI ( body mass index ) range 18 30 kg/m2 , inclusive 6 . Minimum weight 50 kg 7 . Serum Creatinine ≤ ULN ( upper limit normal ) estimate creatinine clearance screen ≥ 80 mL/min per CockcroftGault equation 8 . Total serum bilirubin ≤ ULN ( may repeat confirm eligibility ) 9 . Serum aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ ULN ( may repeat confirm eligibility ) 10 . Male subject must either sterile agree use Checkin 90 day follow last dose AC430 , acceptable form birth control . 11 . Female participant must either nonchildbearing potential agree use acceptable form birth control . Important 1 . History clinically significant drug allergy 2 . Participation another clinical trial receipt Investigational Product within 90 day dose administration ( 5 halflives , whichever long ) 3 . Major surgery within 90 day study enrollment 4 . Use prescription , counter , herbal medication supplement , include oral contraceptive within 14 day checkin 5 . A history drug abuse history alcohol abuse within 1 year prior Screening 6 . Current recent ( within 30 day enrollment ) use tobacco nicotine product 7 . Consumption alcohol contain beverage &gt; average 14 drink per week unwillingness refrain ethanol consumption confine study unit 8 . Inadequate venous access would interfere obtain blood sample 9 . Recipients blood transfusion transfusion blood plasma product , within 90 day study drug administration 10 . Donation blood ≥ 500 mL within 2 month study drug administration 11 . History positive laboratory evidence Human immunodeficiency virus ( HIV ) , Hepatitis B antigen antibody , Hepatitis C , history Tuberculosis ( TB ) infection , positive result Quantiferon Gold test 12 . Prolonged average correct QTc Fridericia 's correction factor ( QTcF ) interval screen electrocardiogram ( ECG ) triplicate ( ≥ 450 m male ≥ 470 ms female ) 13 . Abnormal laboratory value consider clinically significant Investigator 14 . History cancer 15 . History eat disorder within past 3 month 16 . History seizure disorder clinically significant head injury 17 . Positive urine drug screen drug abuse include alcohol 18 . Active infection within 90 day checkin 19 . Medical condition , serious intercurrent illness , cardiovascular , pulmonary , neurologic , psychiatric , renal , hepatic gastrointestinal disease , extenuate circumstance , judgment Principal Investigator , could jeopardize subject safety interfere objective study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>